Skip to main content
Top
Published in: Netherlands Heart Journal 3/2012

Open Access 01-03-2012 | Original article

Levels and trends in cardiovascular risk factors and drug treatment in 4837 elderly Dutch myocardial infarction patients between 2002 and 2006

Authors: S. S. Soedamah-Muthu, J. M. Geleijnse, E. J. Giltay, J. de Goede, L. M. Oude Griep, E. Waterham, A. M. Teitsma-Jansen, B. J. M. Mulder, M.-J. de Boer, J. W. Deckers, P. L. Zock, D. Kromhout, for the Alpha Omega Trial Group

Published in: Netherlands Heart Journal | Issue 3/2012

Login to get access

Abstract

Background

It is important to gain insight into opportunities for secondary prevention of cardiovascular disease. Our aim was to investigate levels and trends in cardiovascular risk factors and drug treatment in Dutch post-myocardial infarction (MI) patients between 2002 and 2006 and to make comparisons with the EUROASPIRE surveys (1999–2007).

Methods

We analysed data from 4837 post-MI patients (aged 69 years, 78% men) from 32 Dutch hospitals, using baseline cross-sectional data from the Alpha Omega Trial.

Results

Between 2002 and 2006, significant declines were found in the prevalence of smoking (23% to 16%, p < 0.001), hypercholesterolaemia (≥5 mmol/l; 54% to 27%, p < 0.0001) and hypertension (≥140/90 mmHg; 58% to 48%, p < 0.001). The prevalence of antithrombotic drugs was high (97%). The prevalence of lipid-modifying drugs and antihypertensives was high, and increased (74% to 90%, p < 0.0001 and 82% to 93%, p < 0.001, respectively). The prevalence of obesity (27%) was high in 2002 and decreased to 24% in 2006, albeit not significantly. Diabetes prevalence was high and increased between 2002 and 2006 (18% to 22%, p = 0.02). In comparison with EUROASPIRE patients, who were on average 8–10 years younger, our study in 2006 included patients with lower levels of obesity, hypertension, hypercholesterolaemia, diabetes and lower use of antiplatelets and β-blockers, but similar levels of lipid-modifying drugs.

Conclusions

This study showed that older Dutch post-MI patients were adequately treated with drugs, and that risk factors reached lower levels than in the younger EUROASPIRE patients. However, there is room for improvement in diet and lifestyle, given the high prevalence of smoking, obesity, and diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mackay J, Mensah G, WHO. The atlas of heart disease and stroke. 1st ed. Geneva: World Health Organization; 2004. Mackay J, Mensah G, WHO. The atlas of heart disease and stroke. 1st ed. Geneva: World Health Organization; 2004.
2.
go back to reference Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–57.PubMedCrossRef Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747–57.PubMedCrossRef
3.
go back to reference Vaartjes I, van Dis I, Visseren FLJ, et al. (2009) Cardiovascular diseases in the Netherlands, 2009. In: Visseren FLJ, van Dis I (ed) Netherlands Heart Foundation Hart-en Vaatziekten in Nederland the Hague, the Netherlands: Dutch heart foundation Vaartjes I, van Dis I, Visseren FLJ, et al. (2009) Cardiovascular diseases in the Netherlands, 2009. In: Visseren FLJ, van Dis I (ed) Netherlands Heart Foundation Hart-en Vaatziekten in Nederland the Hague, the Netherlands: Dutch heart foundation
4.
go back to reference Davies AR, Smeeth L, Grundy EM. Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005. Eur Heart J. 2007;28:2142–7.PubMedCrossRef Davies AR, Smeeth L, Grundy EM. Contribution of changes in incidence and mortality to trends in the prevalence of coronary heart disease in the UK: 1996 2005. Eur Heart J. 2007;28:2142–7.PubMedCrossRef
5.
go back to reference Arveiler D, Wagner A, Ducimetiere P, et al. Trends in coronary heart disease in France during the second half of the 1990s. Eur J Cardiovasc Prev Rehabil. 2005;12:209–15.PubMedCrossRef Arveiler D, Wagner A, Ducimetiere P, et al. Trends in coronary heart disease in France during the second half of the 1990s. Eur J Cardiovasc Prev Rehabil. 2005;12:209–15.PubMedCrossRef
6.
go back to reference Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929–40.PubMedCrossRef Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929–40.PubMedCrossRef
7.
go back to reference Geleijnse JM, Giltay EJ, Schouten EG, et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J. 2010;159:539–46.PubMedCrossRef Geleijnse JM, Giltay EJ, Schouten EG, et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am Heart J. 2010;159:539–46.PubMedCrossRef
8.
go back to reference Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–26.PubMedCrossRef Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–26.PubMedCrossRef
9.
go back to reference Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRef Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRef
10.
go back to reference Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed
11.
go back to reference WHO. WHO Collaborating Centre for Drug Statistics Methodology, Anatomical Therapeutic Chemical Classification System (ATC). World Health Organization, Oslo (2009). WHO. WHO Collaborating Centre for Drug Statistics Methodology, Anatomical Therapeutic Chemical Classification System (ATC). World Health Organization, Oslo (2009).
12.
go back to reference Tukey JW. Some selected quick and easy methods of statistical analysis. Trans N Y Acad Sci. 1953;16:88–97.PubMed Tukey JW. Some selected quick and easy methods of statistical analysis. Trans N Y Acad Sci. 1953;16:88–97.PubMed
13.
go back to reference Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82–93.PubMedCrossRef Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365:82–93.PubMedCrossRef
14.
go back to reference Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37–45.PubMedCrossRef Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37–45.PubMedCrossRef
15.
go back to reference Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790–7.PubMedCrossRef Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790–7.PubMedCrossRef
16.
go back to reference Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1–S113.PubMedCrossRef Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1–S113.PubMedCrossRef
17.
go back to reference Iestra JA, Kromhout D, van der Schouw YT, et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation. 2005;112:924–34.PubMedCrossRef Iestra JA, Kromhout D, van der Schouw YT, et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. Circulation. 2005;112:924–34.PubMedCrossRef
18.
go back to reference Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.PubMedCrossRef Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2010;7:e1000252.PubMedCrossRef
19.
go back to reference Leon H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ (Clinical research ed). 2008;337:a2931.CrossRef Leon H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ (Clinical research ed). 2008;337:a2931.CrossRef
Metadata
Title
Levels and trends in cardiovascular risk factors and drug treatment in 4837 elderly Dutch myocardial infarction patients between 2002 and 2006
Authors
S. S. Soedamah-Muthu
J. M. Geleijnse
E. J. Giltay
J. de Goede
L. M. Oude Griep
E. Waterham
A. M. Teitsma-Jansen
B. J. M. Mulder
M.-J. de Boer
J. W. Deckers
P. L. Zock
D. Kromhout
for the Alpha Omega Trial Group
Publication date
01-03-2012
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 3/2012
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-012-0248-z

Other articles of this Issue 3/2012

Netherlands Heart Journal 3/2012 Go to the issue